Notícias e Atividades da 5AM Ventures

Veja o organograma con seus 24 executivos principais

Biografias mais buscadas da 5AM Ventures

• Andrew Schwab, Founder and Co-Managing Partner
• Kush Parmar, Co-Managing Partner
• John Diekman, Founding Partner

Recentes movimentos de executivos em 5AM Ventures

• Lauren Daniel antes Chief Compliance Officer and Deputy General Counsel, foi promovido a General Counsel and Chief Compliance Officer  (Notícia publicada em 5 de março de 2026).
• Paula Soteropoulos, Venture Partner, deixou a Companhia  (Notícia publicada em 24 de fevereiro de 2026).
• Zoë Rubin, ingressou na Companhia como Director of Compliance  (Notícia publicada em 24 de fevereiro de 2026).

Clique aqui para ver outras movimentos em 5AM Ventures

Criar um alerta
para seguir os movimentos de executivos da 5AM Ventures.

5AM Ventures possui 1.642 concorrentes concorrentes Griffin Gaming Partners (Estados Unidos), BlackRock (Estados Unidos) e KKR (Estados Unidos).

Popular M&A news in Fundo

• DigitalBridge Group has announced the acquisition of ArcLight Capital Partners  (publicado em 3 de junho de 2026).
• Prime Capital Financial adquiriu Access Capital Partners (publicado em 2 de junho de 2026).
• Frazier Healthcare Partners adquiriu Altruix (publicado em 29 de maio de 2026).

Outros contatos sugeridos na indústria do Fundo

• Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
• Salim Ramji - Chief Executive Officer and Director da Vanguard
• Scott Nuttall - Co-Chief Executive Officer and Director da KKR

Saiba mais sobre a indústria do Fundo

Últimos comunicados de imprensa de 5AM Ventures

• NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress - Nodthera
• Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
• Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
• Entrada Therapeutics | Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
• News – Page 130 – 5AM Ventures
• Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer | Arvinas
• CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation • Tue, 04/28/2026 - 08:00
• Precede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026 | Precede Biosciences New
• Entrada Therapeutics | Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
• Fellow Health Appoints Industry Executive Paul Kappelman as Independent Chairman of the Board
• View more press releases Close

Redes sociais sobre 5AM Ventures

• 5AM Ventures na Wikipedia, Google News e Yahoo Finance
• 5AM Ventures na LinkedIn, X (Twitter) e YouTube